Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Blocking Interfering Microbes: Irinotecan is a widely used anticancer pro-drug that is converted in the liver into the active form, but when it gets into the gut, the normally benign microbial flora can convert it into the toxic form, which kills the rapidly multiplying gut epithelium as it would kill rapidly dividing tumor cells, and thus causes diarrhea. Wallace et al. (p. 831 ; see the Perspective by Patel and Kaufmann ) used high-throughput screening to identify inhibitors that target the offending bacterial enzyme, β-glucuronidase, without killing the bacteria or affecting orthologous mammalian enzymes. Crystal structures revealed the molecular basis of selectivity, and in vivo studies showed that an inhibitor protected mice from irinotecan-induced toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“Toxic or adverse consequences can also ensue, as is the case for irinotecan (Wallace et al., 2010)”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
In the citing paper
“Notably, β-glucuronidase inhibitors are capable of rescuing mice from drug toxicity.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“This specificity towards the bacterial enzymes was revealed with the assistance of crystallography and bioinformatics, which demonstrated that these inhibitors interacted with a “bacterial loop” that is highly conserved and well distributed across the gut bacteria enzymes, but is absent from the mammalian enzyme146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“The answer appears to be yes for the bacterial β-glucuronidases, for which multiple inhibitors now exist that have minimal impact on the mammalian homolog143–146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007) · Nature · doi:10.1038/nature06244 · Cited by 6,091
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Gut flora in health and disease
Guarner, F., & Malagelada, J.-R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12489-0 · Cited by 3,365
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
CDD: specific functional annotation with the Conserved Domain Database
Marchler-Bauer, A., Anderson, J. B., Chitsaz, F., Derbyshire, M. K., DeWeese-Scott, C., Fong, J. H., Geer, L. Y., Geer, R. C., Gonzales, N. R., Gwadz, M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn845 · Cited by 1,071
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Three-dimensional structure of β-galactosidase from E. coli.
Jacobson, R. H., Zhang, X.-J., DuBose, R. F., & Matthews, B. W. (1994) · Nature · doi:10.1038/369761a0 · Cited by 600
Research works printed but not linked: 4
- Mathijssen RHJ Clin Cancer Res 7 2182 2001 11489791
- Basińska A Floriańczyk B Ann Univ Mariae Curie Sklodowska Med 58 386 2003 15323223
- Jain S Nat Struct Mol Biol 3 375 1996 · DOI · Paper page
- Brattain MG Fine WD Khaled FM Thompson J Brattain DE Cancer Res 41 1751 1981 7214343
Cited by
Items 201–300 of 1,001
Microbiota–drug interactions: Impact on metabolism and efficacy of therapeutics
Wilkinson, E. M., Ilhan, Z. E., & Herbst‐Kralovetz, M. M. (2018) · Maturitas · doi:10.1016/j.maturitas.2018.03.012 · Cited by 102
Systematically investigating the impact of medication on the gut microbiome
Maier, L., & Typas, A. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.11.001 · Cited by 98
Mechanisms of gastrointestinal microflora on drug metabolism in clinical practice
Sun, C., Chen, L., & Shen, Z. (2019) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2019.09.011 · Cited by 97
Sommer, F., & Bäckhed, F. (2016) · BioEssays · doi:10.1002/bies.201500151 · Cited by 91
Rigby, R. J., Carr, J. S., Orgel, K., King, S. L., Lund, P. K., & Dekaney, C. M. (2016) · Gut Microbes · doi:10.1080/19490976.2016.1215806 · Cited by 96
The Clinical Link between Human Intestinal Microbiota and Systemic Cancer Therapy
Aarnoutse, R., Ziemons, J., Penders, J., Rensen, S. S., de Vos-Geelen, J., & Smidt, M. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174145 · Cited by 83
Secombe, K. R., Coller, J. K., Gibson, R. J., Wardill, H. R., & Bowen, J. M. (2019) · International Journal of Cancer · doi:10.1002/ijc.31836 · Cited by 89
Mishima, Y., & Sartor, R. B. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01618-1 · Cited by 98
The gut microbiome and hypertension
Pevsner‐Fischer, M., Blacher, E., Tatirovsky, E., Ben‐Dov, I. Z., & Elinav, E. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000293 · Cited by 93
Gut Microbial β-Glucuronidase Inhibition via Catalytic Cycle Interception
Pellock, S. J., Creekmore, B. C., Walton, W. G., Mehta, N., Biernat, K. A., Cesmat, A. P., Ariyarathna, Y., Dunn, Z. D., Li, B., Jin, J., et al. (2018) · ACS Central Science · doi:10.1021/acscentsci.8b00239 · Cited by 79
Self-citationMetabolic functions of the human gut microbiota: the role of metalloenzymes
Rajakovich, L. J., & Balskus, E. P. (2019) · Natural Product Reports · doi:10.1039/c8np00074c · Cited by 96
Characterization of Differential Tissue Abundance of Major Non-CYP Enzymes in Human
Basit, A., Neradugomma, N. K., Wolford, C. C., Fan, P. W., Murray, B. P., Takahashi, R., Khojasteh, S. C., Smith, B. J., Heyward, S. A., Totah, R. A., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00559 · Cited by 92
Fidelle, M., Yonekura, S., Picard, M., Cogdill, A., Hollebecque, A., Roberti, M. P., & Zitvogel, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600886 · Cited by 81
Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy
Yue, B., Gao, R., Wang, Z., & Dou, W. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.710945 · Cited by 94
Cross, T.-W., Simpson, A. M. R., Lin, C.-Y., Hottmann, N. M., Bhatt, A. P., Pellock, S. J., Nelson, E. R., Loman, B. R., Wallig, M. A., Vivas, E. I., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2295429 · Cited by 95
Self-citationAlleviation of Gut Inflammation by Cdx2/Pxr Pathway in a Mouse Model of Chemical Colitis
Dou, W., Mukherjee, S., Li, H., Venkatesh, M., Wang, H., Kortagere, S., Peleg, A., Chilimuri, S. S., Wang, Z., Feng, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036075 · Cited by 91
Self-citationKong, R., Liu, T., Zhu, X., Ahmad, S., Williams, A. L., Phan, A. T., Zhao, H., Scott, J. E., Yeh, L.-A., & Wong, S. T. C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0395 · Cited by 90
“Clin Cancer Res; 20(13) July 1, 2014 Clinical Cancer Research 3522”
BackgroundMethodInfluentialSelf-citationUtzeri, E., & Usai, P. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i22.3954 · Cited by 83
Hameed, A. S. S., Rawat, P. S., Meng, X., & Liu, W. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107576 · Cited by 97
Adapting Cancer Immunotherapy Models for the Real World
Klevorn, L. E., & Teague, R. M. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.03.010 · Cited by 88
Jayakumar, S., & Loomba, R. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15314 · Cited by 84
Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
Swami, U., Goel, S., & Mani, S. (2013) · Current Drug Targets · doi:10.2174/1389450111314070007 · Cited by 88
Self-citationChemotherapy-induced gastrointestinal toxicity: Pathogenesis and current management
He, Y., Zheng, J., Ye, B., Dai, Y., & Nie, K. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115787 · Cited by 87
High-Throughput Screening for the Discovery of Enzyme Inhibitors
Lloyd, M. D. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00523 · Cited by 89
Gut microbiome in gastrointestinal cancer: a friend or foe?
Liu, Y., Baba, Y., Ishimoto, T., Gu, X. J., Zhang, J., Nomoto, D., Okadome, K., Baba, H., & Qiu, P. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.69331 · Cited by 85
Insights into gastrointestinal microbiota-generated ginsenoside metabolites and their bioactivities
Yang, L., Zou, H., Gao, Y., Luo, J., Xie, X.-N., Meng, W., Zhou, H., & Tan, Z. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1714645 · Cited by 84
Gut dysbiosis-derived β-glucuronidase promotes the development of endometriosis
Wei, Y., Tan, H., Yang, R., Yang, F., Liu, D., Huang, B., Ouyang, L., Lei, S., Wang, Z., Jiang, S., et al. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.03.032 · Cited by 84
Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation
Sun, J., Song, S., Liu, J., Chen, F., Li, X., & Wu, G. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00678-x · Cited by 89
Wang, Y., Xie, H., Ying, K., Xie, B., Chen, X., Yang, B., Jin, J., Wan, J., Li, T., Han, W., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120705 · Cited by 82
Self-citationEvaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice
Pedroso, S. H. S. P., Vieira, A. T., Bastos, R. W., de Oliveira, J. S., Cartelle, C. T., Arantes, R. M. E., Soares, P. M. G., Generoso, S. D. V., Cardoso, V. N., Teixeira, M. M., et al. (2015) · Microbiology · doi:10.1099/mic.0.000149 · Cited by 90
Mima, K., Ogino, S., Nakagawa, S., Sawayama, H., Kinoshita, K., Krashima, R., Ishimoto, T., Imai, K., Iwatsuki, M., Hashimoto, D., et al. (2017) · Surgical Oncology · doi:10.1016/j.suronc.2017.07.011 · Cited by 84
Tesei, D., Jewczynko, A., Lynch, A., & Urbaniak, C. (2022) · Life · doi:10.3390/life12040495 · Cited by 88
Larsbrink, J., Izumi, A., Ibatullin, F. M., Nakhai, A., Gilbert, H. J., Davies, G. J., & Brumer, H. (2011) · Biochemical Journal · doi:10.1042/bj20110299 · Cited by 88
Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?
Sharma, A., Buschmann, M. M., & Gilbert, J. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1437 · Cited by 86
Human gut bacterial β-glucuronidase inhibition: An emerging approach to manage medication therapy
Wang, P., Jia, Y., Wu, R., Chen, Z., & Yan, R. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114566 · Cited by 85
Sharma, A. K., Jaiswal, S. K., Chaudhary, N., & Sharma, V. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-10203-6 · Cited by 80
Stem Cells for Next Level Toxicity Testing in the 21st Century
Fritsche, E., Haarmann‐Stemmann, T., Kapr, J., Galanjuk, S., Hartmann, J., Mertens, P. R., Kämpfer, A. A. M., Schins, R. P. F., Tigges, J., & Koch, K. (2021) · Small · doi:10.1002/smll.202006252 · Cited by 75
Zou, L., Li, Y., Wang, P., Zhou, K., Hou, J., Jin, Q., Hao, D., Ge, G., & Yang, L. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.020 · Cited by 77
Fu, Q., Zhang, J., Borchardt, D. B., Schlenk, D., & Gan, J. J. (2017) · Environmental Science & Technology · doi:10.1021/acs.est.6b06266 · Cited by 85
Jin, Y., Tian, X., Jin, L., Cui, Y., Liu, T., Yu, Z., Huo, X., Cui, J., Sun, C., Wang, C., et al. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04813 · Cited by 79
A Circadian Clock Transcription Model for the Personalization of Cancer Chronotherapy
Li, X., Ali Mohammad-djafari, A., Dumitru, M., Dulong, S., Filipski, E., Siffroi‐Fernandez, S., Mteyrek, A., Scaglione, F., Guettier, C., Delaunay, F., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1528 · Cited by 78
Structural basis for the regulation of β-glucuronidase expression by human gut Enterobacteriaceae
Little, M. S., Pellock, S. J., Walton, W. G., Tripathy, A., & Redinbo, M. R. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716241115 · Cited by 80
Self-citationAdvances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin
Si, J., Zhao, X., Gao, S., Huang, D., & Sui, M. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118499 · Cited by 77
Maini Rekdal, V., Nol Bernadino, P., Luescher, M. U., Kiamehr, S., Le, C., Bisanz, J. E., Turnbaugh, P. J., Bess, E. N., & Balskus, E. P. (2020) · eLife · doi:10.7554/elife.50845 · Cited by 75
Simpson, J. B., Walker, M. E., Sekela, J. J., Ivey, S. M., Jariwala, P. B., Storch, C. M., Kowalewski, M. E., Graboski, A. L., Lietzan, A. D., Walton, W. G., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.04.018 · Cited by 78
Self-citationBringing microbiome-drug interaction research into the clinic
Guthrie, L., & Kelly, L. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.05.009 · Cited by 83
Engineering microphysiological immune system responses on chips
Miller, C. P., Shin, W., Ahn, E. H., Kim, H. J., & Kim, D.-H. (2020) · Trends in biotechnology · doi:10.1016/j.tibtech.2020.01.003 · Cited by 74
Chen, K. L. A., Liu, X., Zhao, Y. C., Hieronymi, K., Rossi, G., Auvil, L. S., Welge, M. E., Bushell, C., Smith, R. L., Carlson, K. E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26506-1 · Cited by 76
Shi, W., Shen, L., Zou, W., Wang, J., Yang, J., Wang, Y., Liu, B., Xie, L., Zhu, J. Y., & Zhang, Z. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.562463 · Cited by 75
Targeting Regorafenib-Induced Toxicity through Inhibition of Gut Microbial β-Glucuronidases
Ervin, S. M., Hanley, R. P., Lim, L., Walton, W. G., Pearce, K. H., Bhatt, A. P., James, L. I., & Redinbo, M. R. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00663 · Cited by 69
Self-citationLu, L., Dong, J., Liu, Y., Qian, Y., Zhang, G., Zhou, W., Zhao, A., Ji, G., & Xu, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.964793 · Cited by 76
Structure-activity relationships of flavonoids as natural inhibitors against E. coli β-glucuronidase
Weng, Z.-M., Wang, P., Ge, G., Dai, Z., Wu, D., Zou, L., Dou, T., Zhang, T., Yang, L., & Hou, J. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.03.042 · Cited by 74
Pellock, S. J., Walton, W. G., Biernat, K. A., Torres-Rivera, D., Creekmore, B. C., Xu, Y., Liu, J., Tripathy, A., Stewart, L. J., & Redinbo, M. R. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005414 · Cited by 76
Self-citationWhidbey, C., Sadler, N. C., Nair, R. N., Volk, R. F., DeLeon, A. J., Bramer, L. M., Fansler, S. J., Hansen, J. R., Shukla, A. K., Jansson, J. K., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b09668 · Cited by 70
Han, Z., Chen, Q., Zheng, D., Chen, K., Huang, Q., Zhuang, Z., & Zhang, X. (2023) · Advanced Materials · doi:10.1002/adma.202302551 · Cited by 74
Pancreatic Cancer, Gut Microbiota, and Therapeutic Efficacy
Zhang, X., Liu, Q., Liao, Q., & Zhao, Y. (2020) · Journal of Cancer · doi:10.7150/jca.37445 · Cited by 75
Greathouse, K. L., Wyatt, M., Johnson, A. J., Toy, E. P., Khan, J., Dunn, K., Clegg, D. J., & Reddy, S. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100800 · Cited by 73
The Role of Bacteriophages in the Gut Microbiota: Implications for Human Health
Emencheta, S. C., Olovo, C. V., Eze, O. C., Kalu, C. F., BEREBON, D. P., Onuigbo, E. B., Vila, M. M. D. C., Balcão, V. M., & Attama, A. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102416 · Cited by 79
Discovering the Microbial Enzymes Driving Drug Toxicity with Activity-Based Protein Profiling
Jariwala, P. B., Pellock, S. J., Goldfarb, D., Cloer, E. W., Artola, M., Simpson, J. B., Bhatt, A. P., Walton, W. G., Roberts, L. R., Major, M. B., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00788 · Cited by 71
Self-citationMicrobiome Is a Functional Modifier of P450 Drug Metabolism
Dempsey, J. L., & Cui, J. Y. (2019) · Current Pharmacology Reports · doi:10.1007/s40495-019-00200-w · Cited by 68
The Gut Microbiome, Metformin, and Aging
Induri, S. N. R., Kansara, P., Thomas, S. C., Xu, F., Saxena, D. B., & Li, X. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-051920-093829 · Cited by 71
Integrating the gut microbiome and pharmacology
Verdegaal, A. A., & Goodman, A. L. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg8357 · Cited by 72
Kang, M., Kwok, R. T. K., Wang, J., Zhang, H., Lam, J. W. Y., Li, Y., Zhang, P., Zou, H., Gu, X., Li, F., et al. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb00572a · Cited by 67
Orman, M., Bodea, S., Funk, M. A., Campo, A. M.-D., Bollenbach, M., Drennan, C. L., & Balskus, E. P. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b04883 · Cited by 69
Structural Insights into Endobiotic Reactivation by Human Gut Microbiome-Encoded Sulfatases
Ervin, S. M., Simpson, J. B., Gibbs, M. E., Creekmore, B. C., Lim, L., Walton, W. G., Gharaibeh, R. Z., & Redinbo, M. R. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00711 · Cited by 66
Self-citationZhu, R., Lang, T., Yan, W., Zhu, X. G., Huang, X. Y., Yin, Q., & Li, Y. (2021) · Advanced Science · doi:10.1002/advs.202003542 · Cited by 67
Exploring the potential impact of probiotic use on drug metabolism and efficacy
Purdel, C. N., Ungurianu, A., Adam-Dima, I., & Margina, D. M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114468 · Cited by 71
Microbial Determinants of Biochemical Individuality and Their Impact on Toxicology and Pharmacology
Patterson, A. D., & Turnbaugh, P. J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.002 · Cited by 66
Addressing the challenges of applying precision oncology
Shin, S. H., Bode, A. M., & Dong, Z. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0032-z · Cited by 62
Wang, H., Zhou, L., Xie, K., Wu, J., Song, P., Xie, H., Zhou, L., Liu, J., Xu, X., Shen, Y., et al. (2018) · Theranostics · doi:10.7150/thno.26161 · Cited by 65
Self-citationGlioma and the gut–brain axis: opportunities and future perspectives
Dono, A., Nickles, J., Rodriguez-Armendariz, A. G., McFarland, B. C., Ajami, N. J., Ballester, L. Y., Wargo, J. A., & Esquenazi, Y. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac054 · Cited by 68
Relationship Between the Gut Microbiome and Systemic Chemotherapy
Ervin, S. M., Ramanan, S. V., & Bhatt, A. P. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06119-3 · Cited by 67
Microbiota transplantation: Targeting cancer treatment
Wu, X., Zhang, T., Chen, X., Ji, G., & Zhang, F. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.010 · Cited by 67
Gut Microbiota in Lung Cancer: Where Do We Stand?
Georgiou, K. E., Marinov, B. I., Farooqi, A. A., & Gazouli, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910429 · Cited by 65
Roles of microbiota in pancreatic cancer development and treatment
Cruz, M. S., Tintelnot, J., & Gagliani, N. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2320280 · Cited by 68
Roles of microbiota in response to cancer immunotherapy
Inamura, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.026 · Cited by 65
Inamura, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.006 · Cited by 63
Nicholson, J. K., Everett, J. R., & Lindon, J. C. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.646987 · Cited by 60
Impacts of dietary exposure to pesticides on faecal microbiome metabolism in adult twins
Mesnage, R., Bowyer, R. C. E., Balkhi, S. E., Saint‐Marcoux, F., Gardere, A., Ducarmon, Q. R., Geelen, A. R., Zwittink, R. D., Tsoukalas, D., Sarandi, E., et al. (2022) · Environmental Health · doi:10.1186/s12940-022-00860-0 · Cited by 63
The human microbiome is a source of therapeutic drug targets
Wallace, B. D., & Redinbo, M. R. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.04.011 · Cited by 72
Self-citationHassan, M. I., Waheed, A., Grubb, J. H., Klei, H. E., Korolev, S., & Sly, W. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079687 · Cited by 59
A Single Molecule Perspective on the Functional Diversity of in Vitro Evolved β-Glucuronidase
Liebherr, R. B., Renner, M., & Gorris, H. H. (2014) · Journal of the American Chemical Society · doi:10.1021/ja412379p · Cited by 61
Exploring Drug Metabolism by the Gut Microbiota: Modes of Metabolism and Experimental Approaches
Dhurjad, P., Dhavaliker, C., Gupta, K., & Sonti, R. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000669 · Cited by 66
Gut microbiota modulation: a tool for the management of colorectal cancer
Wang, Y., & Li, H. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03378-8 · Cited by 64
Modelling host–microbiome interactions in organ-on-a-chip platforms
Shin, Y. C., Than, N., Min, S., Shin, W., & Kim, H. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00130-9 · Cited by 65
Mechanisms and emerging strategies for irinotecan-induced diarrhea
Xu, S., Lan, H., Huang, C.-Y., Ge, X., & Zhu, J. Y. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176614 · Cited by 61
Microbial endocrinology: the mechanisms by which the microbiota influences host sex steroids
Cotton, S., Clayton, C. A., & Tropini, C. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.03.010 · Cited by 63
Gut microbiome as a novel cardiovascular therapeutic target
Singh, V., Yeoh, B. S., & Vijay–Kumar, M. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.01.002 · Cited by 62
Interaction of antidiabetic α‐glucosidase inhibitors and gut bacteria α‐glucosidase
Tan, K., Tesar, C., Wilton, R., Jedrzejczak, R. P., & Joachimiak, A. (2018) · Protein Science · doi:10.1002/pro.3444 · Cited by 63
Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease
Li, X., & Wang, H. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00507-y · Cited by 63
Self-citationEmerging clinical relevance of microbiome in cancer: promising biomarkers and therapeutic targets
Dai, J.-H., Tan, X.-R., Qiao, H., & Liu, N. (2023) · Protein & Cell · doi:10.1093/procel/pwad052 · Cited by 59
Designing Allosteric Control into Enzymes by Chemical Rescue of Structure
Deckert, K., Budiardjo, S. J., Brunner, L. C., Lovell, S., & Karanicolas, J. (2012) · Journal of the American Chemical Society · doi:10.1021/ja301409g · Cited by 57
Sakurama, H., Kishino, S., 内堀, 良., Yonejima, Y., Ashida, H., Kita, K., Takahashi, S., & Ogawa, J. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-5325-8 · Cited by 61
The Microbiota, Chemical Symbiosis, and Human Disease
Redinbo, M. R. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.09.011 · Cited by 59
Self-citationTralau, T., Sowada, J., & Luch, A. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.990437 · Cited by 58
The Human Microbiota and Prostate Cancer: Friend or Foe?
Massari, F., Mollica, V., Nunno, V. D., Gatto, L., Santoni, M., Scarpelli, M., Cimadamore, A., López-Beltrán, A., Cheng, L., Battelli, N., et al. (2019) · Cancers · doi:10.3390/cancers11040459 · Cited by 62
The microbiome(s) and cancer: know thy neighbor(s)
González‐Sánchez, P., & DeNicola, G. M. (2021) · The Journal of Pathology · doi:10.1002/path.5661 · Cited by 62
Chemotherapy, immunity and microbiota—a new triumvirate?
Karin, M., Jobin, C., & Balkwill, F. R. (2014) · Nature Medicine · doi:10.1038/nm.3473 · Cited by 66
Self-citationInsights from pharmacokinetic models of host-microbiome drug metabolism
Zimmermann‐Kogadeeva, M., Zimmermann, M., & Goodman, A. L. (2019) · Gut Microbes · doi:10.1080/19490976.2019.1667724 · Cited by 60
The role of the gut microbiota in chemotherapy response, efficacy and toxicity: a systematic review
Böhm, D. T. M. M., Russ, E., Guchelaar, H., Ziemons, J., Penders, J., Smidt, M. L., van Best, N., & Deenen, M. J. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01034-0 · Cited by 62
Metadata
- Authors
- Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., & Redinbo, M. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Albert Einstein College of Medicine (US)
- North Carolina Central University (US)
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 831-835
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3110694
- OpenAlex
- W2140145798
- Cited by
- 1,080
- References
- 39
- Citations by year
- 2026: 97 · 2025: 80 · 2024: 103 · 2023: 101 · 2022: 92 · 2021: 92 · 2020: 100 · 2019: 82 · 2018: 70 · 2017: 67 · 2016: 47 · 2015: 33 · 2014: 34 · 2013: 28 · 2012: 29
- FWCI
- 25.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Damon Runyon Cancer Research Foundation
- Golden LEAF Foundation
- National Institutes of Health
- National Cancer Institute (CA 127231, R01CA161879, R01CA127231, CA98468, R01CA098468)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073338)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, chemotherapy-induced diarrhea, enzyme inhibitors, gut microbiota, commensal bacteria, substrate specificity, crystal structure, high-throughput screening, oral administration, colon cancer, drug toxicity
- MeSH terms
- Irinotecan, Animals, Antineoplastic Agents, Phytogenic, Bacteria, Anaerobic, Camptothecin, Colon, Diarrhea, Drug Evaluation, Preclinical, Enzyme Inhibitors, Escherichia coli, Female, Glucuronidase, Humans, Intestinal Mucosa, Mice, Inbred BALB C, Models, Molecular, Prodrugs, Protein Conformation, Crystallography, X-Ray, Escherichia coli Proteins, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.